Image_4_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Image_1_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Image_2_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Image_6_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Image_5_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Image_3_Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.tif

ObjectiveIncreasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort.MethodsThe clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor.ResultsA total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both pConclusionThe C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies.</p

Effects of alfalfa saponin extract on serum lipid levels of rats.

<p>A. Serum TG level. B. Serum TC level. C. Serum HDL-C level. D. Serum LDL-C level. n = 10. TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; * <i>P</i><0.05, Hyperlipidemic group <i>VS.</i> control group; # <i>P</i><0.05, ASE group (both ASE treatment and prevention group) <i>VS.</i> hyperlipidemic group; $ <i>P</i><0.05, ASE group (both ASE treatment and prevention group) <i>VS.</i> control group.</p

Effects of alfalfa saponin extract on mRNA expression of genes in rat liver.

<p>A. <i>Hmgcr</i> mRNA. B. <i>Acat2</i> mRNA. C. <i>Cyp7a1</i> mRNA. D. <i>Ldlr</i> mRNA. n = 10. <i>Hmgcr</i>, 3-Hydroxy-3-methylglutaryl CoA reductase; <i>Acat2</i>, acyl-CoA: cholesterol O-acyltransferase 2; <i>Cyp7a1</i>, cytochrome P450, family 7, subfamily a, polypeptide 1; <i>Ldlr</i>, low-density lipoprotein receptor. * <i>P</i><0.05, Hyperlipidemic group <i>VS.</i> control group; # <i>P</i><0.05, ASE group (both ASE treatment and prevention group) <i>VS.</i> hyperlipidemic group; $ <i>P</i><0.05, ASE group (both ASE treatment and prevention group) <i>VS.</i> control group; + <i>P</i><0.05, ASE prevention group <i>VS.</i> ASE treatment group.</p

Effects of alfalfa saponin extract on body weight gain and relative liver weight of rats.

<p>A. Body weight gain. B. Relative liver weight. n = 10. * <i>P</i><0.05, Hyperlipidemic group <i>VS.</i> control group. $ <i>P</i><0.05, ASE group (both ASE treatment and prevention group) <i>VS.</i> control group. NS, not significant (<i>P</i>>0.05).</p

SYBR Green primer sequences used for real-time RT-PCR.

<p><i>Hmgcr</i>, 3-Hydroxy-3-methylglutaryl CoA reductase; <i>Acat2</i>, acyl-CoA: cholesterol O-acyltransferase 2; <i>Cyp7a1</i>, cytochrome P450, family 7, subfamily a, polypeptide 1; <i>Ldlr</i>, low-density lipoprotein receptor.</p